249 results on '"Miguel Angel Diaz"'
Search Results
2. Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis
- Author
-
Guru Subramanian Guru Murthy, Soyoung Kim, Noel Estrada-Merly, Muhammad Bilal Abid, Mahmoud Aljurf, Amer Assal, Talha Badar, Sherif M. Badawy, Karen Ballen, Amer Beitinjaneh, Jan Cerny, Saurabh Chhabra, Zachariah DeFilipp, Bhagirathbhai Dholaria, Miguel Angel Diaz Perez, Shatha Farhan, Cesar O. Freytes, Robert Peter Gale, Siddhartha Ganguly, Vikas Gupta, Michael R. Grunwald, Nada Hamad, Gerhard C. Hildebrandt, Yoshihiro Inamoto, Tania Jain, Omer Jamy, Mark Juckett, Matt Kalaycio, Maxwell M. Krem, Hillard M. Lazarus, Mark Litzow, Reinhold Munker, Hemant S. Murthy, Sunita Nathan, Taiga Nishihori, Guillermo Ortí, Sagar S. Patel, Marjolein van der Poel, David A. Rizzieri, Bipin N. Savani, Sachiko Seo, Melhem Solh, Leo F. Verdonck, Baldeep Wirk, Jean A. Yared, Ryotaro Nakamura, Betul Oran, Bart Scott, and Wael Saber
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Allogeneic hematopoietic cell transplantation (allo-HCT) remains the only curative treatment for myelofibrosis. However, the optimal conditioning regimen either with reduced-intensity conditioning (RIC) or myeloablative conditioning (MAC) is not well known. Using the Center for International Blood and Marrow Transplant Research database, we identified adults aged ≥18 years with myelofibrosis undergoing allo-HCT between 2008-2019 and analyzed the outcomes separately in the RIC and MAC cohorts based on the conditioning regimens used. Among 872 eligible patients, 493 underwent allo-HCT using RIC (fludarabine/ busulfan n=166, fludarabine/melphalan n=327) and 379 using MAC (fludarabine/busulfan n=247, busulfan/cyclophosphamide n=132). In multivariable analysis with RIC, fludarabine/melphalan was associated with inferior overall survival (hazard ratio [HR]=1.80; 95% confidenec interval [CI]: 1.15-2.81; P=0.009), higher early non-relapse mortality (HR=1.81; 95% CI: 1.12-2.91; P=0.01) and higher acute graft-versus-host disease (GvHD) (grade 2-4 HR=1.45; 95% CI: 1.03-2.03; P=0.03; grade 3-4 HR=2.21; 95%CI: 1.28-3.83; P=0.004) compared to fludarabine/busulfan. In the MAC setting, busulfan/cyclophosphamide was associated with a higher acute GvHD (grade 2-4 HR=2.33; 95% CI: 1.67-3.25; P
- Published
- 2023
- Full Text
- View/download PDF
3. The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis
- Author
-
Matthew Mei, Raju Pillai, Soyoung Kim, Noel Estrada-Merly, Michelle Afkhami, Lixin Yang, Zhuo Meng, Muhammad Bilal Abid, Mahmoud Aljurf, Ulrike Bacher, Amer Beitinjaneh, Christopher Bredeson, Jean-Yves Cahn, Jan Cerny, Edward Copelan, Corey Cutler, Zachariah DeFilipp, Miguel Angel Diaz Perez, Nosha Farhadfar, César O. Freytes, Shahinaz M. Gadalla, Siddhartha Ganguly, Robert Peter Gale, Usama Gergis, Michael R. Grunwald, Betty K. Hamilton, Shahrukh Hashmi, Gerhard C. Hildebrandt, Hillard M. Lazarus, Mark Litzow, Reinhold Munker, Hemant S. Murthy, Sunita Nathan, Taiga Nishihori, Sagar S. Patel, David Rizzieri, Sachiko Seo, Mithun Vinod Shah, Melhem Solh, Leo F. Verdonck, Ravi Vij, Ronald M. Sobecks, Betul Oran, Bart L. Scott, Wael Saber, and Ryotaro Nakamura
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Somatic mutations are recognized as an important prognostic factor in chronic myelomonocytic leukemia (CMML). However, limited data are available regarding their impact on outcomes after allogeneic hematopoietic cell transplantation (HCT). In this registry analysis conducted in collaboration with the Center for International Blood and Marrow Transplantation Registry database/sample repository, we identified 313 adult patients with CMML (median age: 64 years, range, 28- 77) who underwent allogeneic HCT during 2001-2017 and had an available biospecimen in the form of a peripheral blood sample obtained prior to the start of conditioning. In multivariate analysis, a CMML-specific prognostic scoring system (CPSS) score of intermediate-2 (HR=1.46, P=0.049) or high (HR=3.22, P=0.0004) correlated significantly with overall survival. When the molecularly informed CPSS-Mol prognostic model was applied, a high CPSS-Mol score (HR=2 P=0.0079) correlated significantly with overall survival. The most common somatic mutations were in ASXL1 (62%), TET2 (35%), KRAS/NRAS (33% combined), and SRSF2 (31%). DNMT3A and TP53 mutations were associated with decreased overall survival (HR=1.70 [95% CI: 1.11-2.60], P=0.0147 and HR=2.72 [95% CI: 1.37-5.39], P=0.0042, respectively) while DNMT3A, JAK2, and TP53 mutations were associated with decreased disease-free survival (HR=1.66 [95% CI: 1.11-2.49], P=0.0138, HR=1.79 [95% CI: 1.06-3.03], P=0.0293, and HR=2.94 [95% CI: 1.50-5.79], P=0.0018, respectively). The only mutation associated with increased relapse was TP53 (HR=2.94, P=0.0201). Nonetheless, the impact of TP53 mutations specifically should be interpreted cautiously given their rarity in CMML. We calculated the goodness of fit measured by Harrell’s C-index for both the CPSS and CPSS-Mol, which were very similar. In summary, via registry data we have determined the mutational landscape in patients with CMML who underwent allogeneic HCT, and demonstrated an association between CPSS-Mol and transplant outcomes although without major improvement in the risk prediction beyond that provided by the CPSS.
- Published
- 2022
- Full Text
- View/download PDF
4. Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia
- Author
-
Nelli Bejanyan, Soyoung Kim, Kyle M. Hebert, Natasha Kekre, Hisham Abdel-Azim, Ibrahim Ahmed, Mahmoud Aljurf, Sherif M. Badawy, Amer Beitinjaneh, Jaap Jan Boelens, Miguel Angel Diaz, Christopher C. Dvorak, Shahinaz Gadalla, James Gajewski, Robert Peter Gale, Siddhartha Ganguly, Andrew R. Gennery, Biju George, Usama Gergis, David Gómez-Almaguer, Marta Gonzalez Vicent, Hasan Hashem, Rammurti T. Kamble, Kimberly A. Kasow, Hillard M. Lazarus, Vikram Mathews, Paul J. Orchard, Michael Pulsipher, Olle Ringden, Kirk Schultz, Pierre Teira, Ann E. Woolfrey, Blachy Dávila Saldaña, Bipin Savani, Jacek Winiarski, Jean Yared, Daniel J. Weisdorf, Joseph H. Antin, and Mary Eapen
- Subjects
Specialties of internal medicine ,RC581-951 - Abstract
Abstract: Allogeneic bone marrow transplantation (BMT) is curative therapy for the treatment of patients with severe aplastic anemia (SAA). However, several conditioning regimens can be used for BMT. We evaluated transplant conditioning regimens for BMT in SAA after HLA-matched sibling and unrelated donor BMT. For recipients of HLA-matched sibling donor transplantation (n = 955), fludarabine (Flu)/cyclophosphamide (Cy)/antithymocyte globulin (ATG) or Cy/ATG led to the best survival. The 5-year probabilities of survival with Flu/Cy/ATG, Cy/ATG, Cy ± Flu, and busulfan/Cy were 91%, 91%, 80%, and 84%, respectively (P = .001). For recipients of 8/8 and 7/8 HLA allele-matched unrelated donor transplantation (n = 409), there were no differences in survival between regimens. The 5-year probabilities of survival with Cy/ATG/total body irradiation 200 cGy, Flu/Cy/ATG/total body irradiation 200 cGy, Flu/Cy/ATG, and Cy/ATG were 77%, 80%, 75%, and 72%, respectively (P = .61). Rabbit-derived ATG compared with equine-derived ATG was associated with a lower risk of grade II to IV acute graft-versus-host disease (GVHD) (hazard ratio [HR], 0.39; P < .001) but not chronic GVHD. Independent of conditioning regimen, survival was lower in patients aged >30 years after HLA-matched sibling (HR, 2.74; P < .001) or unrelated donor (HR, 1.98; P = .001) transplantation. These data support Flu/Cy/ATG and Cy/ATG as optimal regimens for HLA-matched sibling BMT. Although survival after an unrelated donor BMT did not differ between regimens, use of rabbit-derived ATG may be preferred because of lower risks of acute GVHD.
- Published
- 2019
- Full Text
- View/download PDF
5. Increased overall and bacterial infections following myeloablative allogeneic HCT for patients with AML in CR1
- Author
-
Celalettin Ustun, Soyoung Kim, Min Chen, Amer M. Beitinjaneh, Valerie I. Brown, Parastoo B. Dahi, Andrew Daly, Miguel Angel Diaz, Cesar O. Freytes, Siddhartha Ganguly, Shahrukh Hashmi, Gerhard C. Hildebrandt, Hillard M. Lazarus, Taiga Nishihori, Richard F. Olsson, Kristin M. Page, Genovefa Papanicolaou, Ayman Saad, Sachiko Seo, Basem M. William, John R. Wingard, Baldeep Wirk, Jean A. Yared, Miguel-Angel Perales, Jeffery J. Auletta, Krishna V. Komanduri, Caroline A. Lindemans, and Marcie L. Riches
- Subjects
Specialties of internal medicine ,RC581-951 - Abstract
Abstract: Presumably, reduced-intensity/nonmyeloablative conditioning (RIC/NMA) for allogeneic hematopoietic cell transplantation (alloHCT) results in reduced infections compared with myeloablative conditioning (MAC) regimens; however, published evidence is limited. In this Center for International Blood and Marrow Transplant Research study, 1755 patients (aged ≥40 years) with acute myeloid leukemia in first complete remission were evaluated for infections occurring within 100 days after T-cell replete alloHCT. Patients receiving RIC/NMA (n = 777) compared with those receiving MAC (n = 978) were older and underwent transplantation more recently; however, the groups were similar regarding Karnofsky performance score, HCT–comorbidity index, and cytogenetic risk. One or more infections occurred in 1045 (59.5%) patients (MAC, 595 [61%]; RIC/NMA, 450 [58%]; P = .21) by day 100. The median time to initial infection after MAC conditioning occurred earlier (MAC, 15 days [range,
- Published
- 2019
- Full Text
- View/download PDF
6. Early and late outcomes after cord blood transplantation for pediatric patients with inherited leukodystrophies
- Author
-
Brigitte T.A. van den Broek, Kristin Page, Annalisa Paviglianiti, Janna Hol, Heather Allewelt, Fernanda Volt, Gerard Michel, Miguel Angel Diaz, Victoria Bordon, Tracey O'Brien, Peter J. Shaw, Chantal Kenzey, Amal Al-Seraihy, Peter M. van Hasselt, Andrew R. Gennery, Eliane Gluckman, Vanderson Rocha, Annalisa Ruggeri, Joanne Kurtzberg, and Jaap Jan Boelens
- Subjects
Specialties of internal medicine ,RC581-951 - Abstract
Abstract: Leukodystrophies (LD) are devastating inherited disorders leading to rapid neurological deterioration and premature death. Hematopoietic stem cell transplantation (HSCT) can halt disease progression for selected LD. Cord blood is a common donor source for transplantation of these patients because it is rapidly available and can be used without full HLA matching. However, precise recommendations allowing care providers to identify patients who benefit from HSCT are lacking. In this study, we define risk factors and describe the early and late outcomes of 169 patients with globoid cell leukodystrophy, X-linked adrenoleukodystrophy, and metachromatic leukodystrophy undergoing cord blood transplantation (CBT) at an European Society for Blood and Marrow Transplantation center or at Duke University Medical Center from 1996 to 2013. Factors associated with higher overall survival (OS) included presymptomatic status (77% vs 49%; P = .006), well-matched (≤1 HLA mismatch) CB units (71% vs 54%; P = .009), and performance status (PS) of >80 vs 80 pre-CBT, 50% remained stable, 20% declined to 60 to 80, and 30% to
- Published
- 2018
- Full Text
- View/download PDF
7. Clinical risks and healthcare utilization of hematopoietic cell transplantation for sickle cell disease in the USA using merged databases
- Author
-
Staci D. Arnold, Ruta Brazauskas, Naya He, Yimei Li, Richard Aplenc, Zhezhen Jin, Matt Hall, Yoshiko Atsuta, Jignesh Dalal, Theresa Hahn, Nandita Khera, Carmem Bonfim, Navneet S. Majhail, Miguel Angel Diaz, Cesar O. Freytes, William A. Wood, Bipin N. Savani, Rammurti T. Kamble, Susan Parsons, Ibrahim Ahmed, Keith Sullivan, Sara Beattie, Christopher Dandoy, Reinhold Munker, Susana Marino, Menachem Bitan, Hisham Abdel-Azim, Mahmoud Aljurf, Richard F. Olsson, Sarita Joshi, Dave Buchbinder, Michael J. Eckrich, Shahrukh Hashmi, Hillard Lazarus, David I. Marks, Amir Steinberg, Ayman Saad, Usama Gergis, Lakshmanan Krishnamurti, Allistair Abraham, Hemalatha G. Rangarajan, Mark Walters, Joseph Lipscomb, Wael Saber, and Prakash Satwani
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Advances in allogeneic hematopoietic cell transplantation for sickle cell disease have improved outcomes, but there is limited analysis of healthcare utilization in this setting. We hypothesized that, compared to late transplantation, early transplantation (at age
- Published
- 2017
- Full Text
- View/download PDF
8. Reframing the Policy Discourse: A Comparative Analysis of Teacher Preparation for Rural and Remote Education in Australia, South Africa, and Mexico
- Author
-
Ledger, Susan, Masinire, Alfr, Delgado, Miguel Angel Diaz, and Burgess, Madeline
- Abstract
The Organisation for Economic Cooperation and Development (OECD) has highlighted a 'vicious cycle of decline' in rural, regional and remote (RRR) regions, with significant inequalities in educational outcomes between rural and urban areas. However, interventions have not resulted in transformative or lasting improvements to education in rural contexts. This paper presents a cross-comparative country analysis of current global policy on RRR education. We used a policy analysis framework to interrogate national policy texts concerning teacher education for RRR contexts in three countries - Australia, South Africa and Mexico. A rigorous selection process of the literature yielded 17 key policy texts, which were examined for the influences, practices, language and outcomes relating to teacher education preparation for RRR locales. Findings highlighted a legacy of historical influences and a metrocentric bias in policy texts, with limited examples of assets-based education. We argue that these factors may be perpetuating the significant and persistent disadvantage in RRR education. We recommend an alternative policy discourse that recognises the productivities and potentialities of an assets-based approach within the local context, where school leaders and teachers are positioned as central change agents in RRR education.
- Published
- 2021
9. Haploidentical vs. sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia
- Author
-
Wieduwilt, Matthew J, Metheny, Leland, Zhang, Mei-Jie, Wang, Hai-Lin, Estrada-Merly, Noel, Marks, David I, Al-Homsi, A Samar, Muffly, Lori, Chao, Nelson J, Rizzieri, David, Gale, Robert Peter, Gadalla, Shahinaz M, Cairo, Mitchell S, Mussetti, Alberto, Gore, Steven D, Bhatt, Vijaya Raj, Patel, Sagar S, Michelis, Fotios V, Inamoto, Yoshihiro, Badawy, Sherif M, Copelan, Edward, Palmisiano, Neil, Kharfan-Dabaja, Mohamed A, Lazarus, Hillard M, Ganguly, Siddhartha, Bredeson, Christopher N, Perez, Miguel Angel Diaz, Cassaday, Ryan, Savani, Bipin N, Ballen, Karen Kuhn, Martino, Rodrigo, Wirk, Baldeep, Bacher, Ulrike, Aljurf, Mahmoud, Bashey, Asad, Murthy, Hemant S, Yared, Jean A, Aldoss, Ibrahim, Farhadfar, Nosha, Liu, Hongtao, Abdel-Azim, Hisham, Waller, Edmund K, Solh, Melhem, Seftel, Matthew, van der Poel, Marjolein WM, Grunwald, Michael Richard, Liesveld, Jane L, Kamble, Rammurti T, McGuirk, Joseph P, Munker, Reinhold, Cahn, Jean-Yves, Lee, Jong Wook, Freytes, Cesar O, Krem, Maxwell, Winestone, Lena E, Gergis, Usama, Nathan, Sunita, Olsson, Richard F, Verdonck, Leo F, Sharma, Akshay, Ringden, Olle, Friend, Brian D, Cerny, Jan, Choe, Hannah K, Chhabra, Saurabh, Nishihori, Taiga, Seo, Sachiko, George, Biju, Baxter-Lowe, Lee Ann, Hildebrandt, Gerhard C, de Lima, Marcos, Litzow, Mark R, Kebriaei, Partow, Hourigan, Christopher S, Abid, Muhammad Bilal, Weisdorf, Daniel J, and Saber, Wael
- Subjects
Rare Diseases ,Cancer ,Pediatric ,Pediatric Cancer ,Stem Cell Research - Nonembryonic - Human ,Orphan Drug ,Hematology ,Stem Cell Research ,Transplantation ,Good Health and Well Being ,Fetal Blood ,Hematopoietic Stem Cell Transplantation ,Humans ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,Retrospective Studies ,Siblings ,Unrelated Donors - Abstract
The role of haploidentical hematopoietic cell transplantation (HCT) using posttransplant cyclophosphamide (PTCy) for acute lymphoblastic leukemia (ALL) is being defined. We performed a retrospective, multivariable analysis comparing outcomes of HCT approaches by donor for adults with ALL in remission. The primary objective was to compare overall survival (OS) among haploidentical HCTs using PTCy and HLA-matched sibling donor (MSD), 8/8 HLA-matched unrelated donor (MUD), 7 /8 HLA-MUD, or umbilical cord blood (UCB) HCT. Comparing haploidentical HCT to MSD HCT, we found that OS, leukemia-free survival (LFS), nonrelapse mortality (NRM), relapse, and acute graft-versus-host disease (aGVHD) were not different but chronic GVHD (cGVHD) was higher in MSD HCT. Compared with MUD HCT, OS, LFS, and relapse were not different, but MUD HCT had increased NRM (hazard ratio [HR], 1.42; P = .02), grade 3 to 4 aGVHD (HR, 1.59; P = .005), and cGVHD. Compared with 7/8 UD HCT, LFS and relapse were not different, but 7/8 UD HCT had worse OS (HR, 1.38; P = .01) and increased NRM (HR, 2.13; P ≤ .001), grade 3 to 4 aGVHD (HR, 1.86; P = .003), and cGVHD (HR, 1.72; P ≤ .001). Compared with UCB HCT, late OS, late LFS, relapse, and cGVHD were not different but UCB HCT had worse early OS (≤18 months; HR, 1.93; P < .001), worse early LFS (HR, 1.40; P = .007) and increased incidences of NRM (HR, 2.08; P < .001) and grade 3 to 4 aGVHD (HR, 1.97; P < .001). Haploidentical HCT using PTCy showed no difference in survival but less GVHD compared with traditional MSD and MUD HCT and is the preferred alternative donor HCT option for adults with ALL in complete remission.
- Published
- 2022
10. EFECTOS DE LA PANDEMIA COVID-19 EN LA PRODUCCIÓN ESTATAL DE MÉXICO
- Author
-
Carreño, Miguel Ángel Díaz, Reyes, Pablo Mejía, and Rojas, Liliana Rendón
- Published
- 2022
11. Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113 AML patients
- Author
-
Boyiadzis, Michael, Zhang, Mei-Jie, Chen, Karen, Abdel-Azim, Hisham, Abid, Muhammad Bilal, Aljurf, Mahmoud, Bacher, Ulrike, Badar, Talha, Badawy, Sherif M., Battiwalla, Minoo, Bejanyan, Nelli, Bhatt, Vijaya Raj, Brown, Valerie I., Castillo, Paul, Cerny, Jan, Copelan, Edward A., Craddock, Charles, Dholaria, Bhagirathbhai, Perez, Miguel Angel Diaz, Ebens, Christen L., Gale, Robert Peter, Ganguly, Siddhartha, Gowda, Lohith, Grunwald, Michael R., Hashmi, Shahrukh, Hildebrandt, Gerhard C., Iqbal, Madiha, Jamy, Omer, Kharfan-Dabaja, Mohamed A., Khera, Nandita, Lazarus, Hillard M., Lin, Richard, Modi, Dipenkumar, Nathan, Sunita, Nishihori, Taiga, Patel, Sagar S., Pawarode, Attaphol, Saber, Wael, Sharma, Akshay, Solh, Melhem, Wagner, John L., Wang, Trent, Williams, Kirsten M., Winestone, Lena E., Wirk, Baldeep, Zeidan, Amer, Hourigan, Christopher S., Litzow, Mark, Kebriaei, Partow, de Lima, Marcos, Page, Kristin, and Weisdorf, Daniel J.
- Published
- 2023
- Full Text
- View/download PDF
12. An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis
- Author
-
Jimenez Jimenez, Antonio M, De Lima, Marcos, Komanduri, Krishna V, Wang, Trent P, Zhang, Mei-Jie, Chen, Karen, Abdel-Azim, Hisham, Abid, Muhammad Bilal, Aljurf, Mahmoud, Alkhateeb, Hassan, Assal, Amer, Bacher, Ulrike, Baron, Frédéric, Battiwalla, Minoo, Beitinjaneh, Amer, Bejanyan, Nelli, Bhatt, Vijaya Raj, Byrne, Michael, Cahn, Jean-Yves, Cairo, Mitchell, Castillo, Paul, Copelan, Edward, DeFilipp, Zachariah, Perez, Miguel Angel Diaz, Elsawy, Mahmoud, Gale, Robert Peter, George, Biju, Grunwald, Michael R, Hildebrandt, Gerhard C, Hogan, William J, Kanakry, Christopher G, Kansagra, Ankit, Kharfan-Dabaja, Mohamed A, Khera, Nandita, Krem, Maxwell M, Lazaryan, Aleksandr, Maakaron, Joseph, Martino, Rodrigo, McGuirk, Joseph, Michelis, Fotios V, Milone, Giuseppe, Mishra, Asmita, Murthy, Hemant S, Mussetti, Alberto, Nathan, Sunita, Nishihori, Taiga, Olsson, Richard F, Palmisiano, Neil, Patel, Sagar, Saad, Ayman, Seo, Sachiko, Sharma, Akshay, Solh, Melhem, Verdonck, Leo F, Wirk, Baldeep, Yared, Jean A, Litzow, Mark, Kebriaei, Partow, Hourigan, Christopher S, Saber, Wael, and Weisdorf, Daniel
- Subjects
Biomedical and Clinical Sciences ,Cardiovascular Medicine and Haematology ,Oncology and Carcinogenesis ,Hematology ,Genetics ,Transplantation ,Pediatric Research Initiative ,Childhood Leukemia ,Stem Cell Research ,Cancer ,Clinical Research ,Pediatric Cancer ,Rare Diseases ,Pediatric ,Stem Cell Research - Nonembryonic - Human ,4.1 Discovery and preclinical testing of markers and technologies ,Detection ,screening and diagnosis ,Good Health and Well Being ,Hematopoietic Stem Cell Transplantation ,Humans ,Leukemia ,Myeloid ,Acute ,Retrospective Studies ,Risk Assessment ,Transplantation Conditioning ,Transplantation ,Homologous ,Clinical Sciences ,Immunology ,Cardiovascular medicine and haematology ,Oncology and carcinogenesis - Abstract
Cytogenetic and molecular abnormalities are known to influence post-transplant outcomes in acute myeloid leukemia (AML) but data assessing the prognostic value of combined genetic models in the HCT setting are limited. We developed an adapted European LeukemiaNet (aELN) risk classification based on available genetic data reported to the Center for International Blood and Marrow Transplant Research, to predict post-transplant outcomes in 2289 adult AML patients transplanted in first remission, between 2013 and 2017. Patients were stratified according to aELN into three groups: favorable (Fav, N = 181), intermediate (IM, N = 1185), and adverse (Adv, N = 923). Univariate analysis demonstrated significant differences in 2-year overall survival (OS) (Fav: 67.7%, IM: 64.9% and Adv: 53.9%; p
- Published
- 2021
13. Optimal Donor for African Americans with Hematologic Malignancy: HLA-Haploidentical Relative or Umbilical Cord Blood Transplant
- Author
-
Solomon, Scott R, Martin, Andrew St, Zhang, Mei-Jie, Ballen, Karen, Bashey, Asad, Battiwalla, Minoo, Baxter-Lowe, Lee Ann, Brunstein, Claudio, Chhabra, Saurabh, Perez, Miguel Angel Diaz, Fuchs, Ephraim J, Ganguly, Siddhartha, Hardy, Nancy, Hematti, Peiman, McGuirk, Joseph, Peres, Edward, Ringden, Olle, Rizzieri, David, Romee, Rizwan, Solh, Melhem, Szwajcer, David, van der Poel, Marjolein, Waller, Edmund, William, Basem M, and Eapen, Mary
- Subjects
Biomedical and Clinical Sciences ,Cardiovascular Medicine and Haematology ,Immunology ,Stem Cell Research ,Stem Cell Research - Nonembryonic - Human ,Clinical Research ,Transplantation ,Hematology ,Stem Cell Research - Umbilical Cord Blood/ Placenta - Human ,Rare Diseases ,Cancer ,Regenerative Medicine ,Stem Cell Research - Umbilical Cord Blood/ Placenta ,Good Health and Well Being ,Black or African American ,Cord Blood Stem Cell Transplantation ,Fetal Blood ,Graft vs Host Disease ,Hematologic Neoplasms ,Hematopoietic Stem Cell Transplantation ,Histocompatibility Testing ,Humans ,Alternative donor ,African American ,Caucasian ,race ,leukemia ,transplant-related mortality ,Clinical Sciences ,Cardiovascular medicine and haematology - Abstract
Although hematopoietic cell transplantation from an HLA-matched unrelated donor is potentially curative for hematologic malignancies, survival is lower for African Americans compared with Caucasians. Because only approximately 20% of African Americans will have an HLA-matched unrelated donor, many of these patients undergo HLA-haploidentical relative or umbilical cord blood transplantation. In this study, we analyzed outcomes after HLA-haploidentical related donor (n = 249) and umbilical cord blood (n = 118) transplantations in African American patients with hematologic malignancy between 2008 and 2016. The predominant disease was acute myelogenous leukemia for recipients of both types of donor grafts. The incidences of grade II-IV and III-IV acute graft-versus-host disease were higher after umbilical cord blood transplantation compared with HLA-haploidentical relative transplantation (56% and 29%, respectively, versus 33% and 11%, respectively; P < .0001). The 2-year incidence of transplantation-related mortality adjusted for age and conditioning regimen intensity was higher after umbilical cord blood transplantation compared with HLA-haploidentical related donor transplantation (31% versus 18%; P = .008); however, there were no between-group differences in the 2-year adjusted incidence of relapse (30% versus 34%; P = .51), overall survival (54% versus 57%; P = .66), or disease-free survival (43% versus 47%; P = .46). Our findings show that the use of HLA-haploidentical and umbilical cord blood transplants expands the access to transplantation with comparable leukemia-free and overall survival for African Americans with hematologic malignancies.
- Published
- 2020
14. Correction to: Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113AML patients
- Author
-
Boyiadzis, Michael, Zhang, Mei-Jie, Chen, Karen, Abdel-Azim, Hisham, Abid, Muhammad Bilal, Aljurf, Mahmoud, Bacher, Ulrike, Badar, Talha, Badawy, Sherif M., Battiwalla, Minoo, Bejanyan, Nelli, Bhatt, Vijaya Raj, Brown, Valerie I., Castillo, Paul, Cerny, Jan, Copelan, Edward A., Craddock, Charles, Dholaria, Bhagirathbhai, Perez, Miguel Angel Diaz, Ebens, Christen L., Gale, Robert Peter, Ganguly, Siddhartha, Gowda, Lohith, Grunwald, Michael R., Hashmi, Shahrukh, Hildebrandt, Gerhard C., Iqbal, Madiha, Jamy, Omer, Kharfan-Dabaja, Mohamed A., Khera, Nandita, Lazarus, Hillard M., Lin, Richard, Modi, Dipenkumar, Nathan, Sunita, Nishihori, Taiga, Patel, Sagar S., Pawarode, Attaphol, Saber, Wael, Sharma, Akshay, Solh, Melhem, Wagner, John L., Wang, Trent, Williams, Kirsten M., Winestone, Lena E., Wirk, Baldeep, Zeidan, Amer, Hourigan, Christopher S., Litzow, Mark, Kebriaei, Partow, de Lima, Marcos, Page, Kristin, and Weisdorf, Daniel J.
- Published
- 2023
- Full Text
- View/download PDF
15. Racial and Socioeconomic Disparities in Long-Term Outcomes in ≥1 Year Allogeneic Hematopoietic Cell Transplantation Survivors: A CIBMTR Analysis
- Author
-
Blue, Brandon J., Brazauskas, Ruta, Chen, Karen, Patel, Jinalben, Zeidan, Amer M., Steinberg, Amir, Ballen, Karen, Kwok, Janette, Rotz, Seth J., Perez, Miguel Angel Diaz, Kelkar, Amar H., Ganguly, Siddhartha, Wingard, John R., Lad, Deepesh, Sharma, Akshay, Badawy, Sherif M., Lazarus, Hillard M., Hashem, Hasan, Szwajcer, David, Knight, Jennifer M., Bhatt, Neel S., Page, Kristin, Beattie, Sara, Arai, Yasuyuki, Liu, Hongtao, Arnold, Staci D., Freytes, César O., Abid, Muhammad Bilal, Beitinjaneh, Amer, Farhadfar, Nosha, Wirk, Baldeep, Winestone, Lena E., Agrawal, Vaibhav, Preussler, Jaime M., Seo, Sachiko, Hashmi, Shahrukh, Lehmann, Leslie, Wood, William A., Rangarajan, Hemalatha G., Saber, Wael, and Majhail, Navneet S.
- Published
- 2023
- Full Text
- View/download PDF
16. Optimal Donor for African Americans with Hematologic Malignancy: HLA-Haploidentical Relative or Umbilical Cord Blood Transplant
- Author
-
Solomon, Scott R., Martin, Andrew St, Zhang, Mei-Jie, Ballen, Karen, Bashey, Asad, Battiwalla, Minoo, Baxter-Lowe, Lee Ann, Brunstein, Claudio, Chhabra, Saurabh, Perez, Miguel Angel Diaz, Fuchs, Ephraim J., Ganguly, Siddhartha, Hardy, Nancy, Hematti, Peiman, McGuirk, Joseph, Peres, Edward, Ringden, Olle, Rizzieri, David, Romee, Rizwan, Solh, Melhem, Szwajcer, David, van der Poel, Marjolein, Waller, Edmund, William, Basem M., and Eapen, Mary
- Published
- 2020
- Full Text
- View/download PDF
17. Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide
- Author
-
Im, Annie, Rashidi, Armin, Wang, Tao, Hemmer, Michael, MacMillan, Margaret L., Pidala, Joseph, Jagasia, Madan, Pavletic, Steven, Majhail, Navneet S., Weisdorf, Daniel, Abdel-Azim, Hisham, Agrawal, Vaibhav, Al-Homsi, A. Samer, Aljurf, Mahmoud, Askar, Medhat, Auletta, Jeffery J., Bashey, Asad, Beitinjaneh, Amer, Bhatt, Vijaya Raj, Byrne, Michael, Cahn, Jean-Yves, Cairo, Mitchell, Castillo, Paul, Cerny, Jan, Chhabra, Saurabh, Choe, Hannah, Ciurea, Stefan, Daly, Andrew, Perez, Miguel Angel Diaz, Farhadfar, Nosha, Gadalla, Shahinaz M., Gale, Robert, Ganguly, Siddhartha, Gergis, Usama, Hanna, Rabi, Hematti, Peiman, Herzig, Roger, Hildebrandt, Gerhard C., Lad, Deepesh P., Lee, Catherine, Lehmann, Leslie, Lekakis, Lazaros, Kamble, Rammurti T., Kharfan-Dabaja, Mohamed A., Khandelwal, Pooja, Martino, Rodrigo, Murthy, Hemant S., Nishihori, Taiga, O'Brien, Tracey A., Olsson, Richard F., Patel, Sagar S., Perales, Miguel-Angel, Prestidge, Tim, Qayed, Muna, Romee, Rizwan, Schoemans, Hélène, Seo, Sachiko, Sharma, Akshay, Solh, Melhem, Strair, Roger, Teshima, Takanori, Urbano-Ispizua, Alvaro, Van der Poel, Marjolein, Vij, Ravi, Wagner, John L., William, Basem, Wirk, Baldeep, Yared, Jean A., Spellman, Steve R., Arora, Mukta, and Hamilton, Betty K.
- Published
- 2020
- Full Text
- View/download PDF
18. Expanded HCT-CI Definitions Capture Comorbidity Better for Younger Patients of Allogeneic HCT for Nonmalignant Diseases
- Author
-
Broglie, Larisa, Friend, Brian D., Chhabra, Saurabh, Logan, Brent R., Bupp, Caitrin, Schiller, Gary, Savani, Bipin N., Stadtmauer, Edward, Abraham, Allistair A., Aljurf, Mahmoud, Badawy, Sherif M., Perez, Miguel Angel Diaz, Guinan, Eva C., Hashem, Hasan, Krem, Maxwell M., Lazarus, Hillard M., Rotz, Seth J., Wirk, Baldeep, Yared, Jean A., Pasquini, Marcelo, Thakar, Monica S., and Sorror, Mohamed L.
- Published
- 2023
- Full Text
- View/download PDF
19. Adapting the HCT-CI Definitions for Children, Adolescents, and Young Adults with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation
- Author
-
Friend, Brian D., Broglie, Larisa, Logan, Brent R., Chhabra, Saurabh, Bupp, Caitrin, Schiller, Gary, Beitinjaneh, Amer, Perez, Miguel Angel Diaz, Guilcher, Gregory M.T., Hashem, Hasan, Hildebrandt, Gerhard C., Krem, Maxwell M., Lazarus, Hillard M., Nishihori, Taiga, Nusrat, Roomi, Rotz, Seth J., Wirk, Baldeep, Wieduwilt, Matthew, Pasquini, Marcelo, Savani, Bipin N., Stadtmauer, Edward A., Sorror, Mohamed L., and Thakar, Monica S.
- Published
- 2023
- Full Text
- View/download PDF
20. Correction to: An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis
- Author
-
Jimenez Jimenez, Antonio M., De Lima, Marcos, Komanduri, Krishna V., Wang, Trent P., Zhang, Mei-Jie, Chen, Karen, Abdel-Azim, Hisham, Abid, Muhammad Bilal, Aljurf, Mahmoud, Alkhateeb, Hassan, Assal, Amer, Bacher, Ulrike, Baron, Frédéric, Battiwalla, Minoo, Beitinjaneh, Amer, Bejanyan, Nelli, Bhatt, Vijaya Raj, Byrne, Michael, Cahn, Jean-Yves, Cairo, Mitchell, Castillo, Paul, Copelan, Edward, DeFilipp, Zachariah, Perez, Miguel Angel Diaz, Elsawy, Mahmoud, Gale, Robert Peter, George, Biju, Grunwald, Michael R., Hildebrandt, Gerhard C., Hogan, William J., Kanakry, Christopher G., Kansagra, Ankit, Kharfan-Dabaja, Mohamed A., Khera, Nandita, Krem, Maxwell M., Lazaryan, Aleksandr, Maakaron, Joseph, Martino, Rodrigo, McGuirk, Joseph, Michelis, Fotios V., Milone, Giuseppe, Mishra, Asmita, Murthy, Hemant S., Mussetti, Alberto, Nathan, Sunita, Nishihori, Taiga, Olsson, Richard F., Palmisiano, Neil, Patel, Sagar, Saad, Ayman, Seo, Sachiko, Sharma, Akshay, Solh, Melhem, Verdonck, Leo F., Wirk, Baldeep, Yared, Jean A., Litzow, Mark, Kebriaei, Partow, Hourigan, Christopher S., Saber, Wael, and Weisdorf, Daniel
- Published
- 2022
- Full Text
- View/download PDF
21. EFECTOS DEL GASTO PÚBLICO EN EL PIB EN LOS ESTADOS DE MÉXICO, 1999-2014
- Author
-
Carreño, Miguel Ángel Díaz, Reyes, Pablo Mejía, Hernández, Marlen R. Reyes, and de la Cruz, Ana Desiderio
- Published
- 2018
22. Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113 AML patients
- Author
-
Michael Boyiadzis, Mei-Jie Zhang, Karen Chen, Hisham Abdel-Azim, Muhammad Bilal Abid, Mahmoud Aljurf, Ulrike Bacher, Talha Badar, Sherif M. Badawy, Minoo Battiwalla, Nelli Bejanyan, Vijaya Raj Bhatt, Valerie I. Brown, Paul Castillo, Jan Cerny, Edward A. Copelan, Charles Craddock, Bhagirathbhai Dholaria, Miguel Angel Diaz Perez, Christen L. Ebens, Robert Peter Gale, Siddhartha Ganguly, Lohith Gowda, Michael R. Grunwald, Shahrukh Hashmi, Gerhard C. Hildebrandt, Madiha Iqbal, Omer Jamy, Mohamed A. Kharfan-Dabaja, Nandita Khera, Hillard M. Lazarus, Richard Lin, Dipenkumar Modi, Sunita Nathan, Taiga Nishihori, Sagar S. Patel, Attaphol Pawarode, Wael Saber, Akshay Sharma, Melhem Solh, John L. Wagner, Trent Wang, Kirsten M. Williams, Lena E. Winestone, Baldeep Wirk, Amer Zeidan, Christopher S. Hourigan, Mark Litzow, Partow Kebriaei, Marcos de Lima, Kristin Page, and Daniel J. Weisdorf
- Subjects
Cancer Research ,Oncology ,Hematology - Published
- 2022
23. Recesiones de México en los albores del siglo XXI
- Author
-
Reyes, Pablo Mejía, Carreño, Miguel Ángel Díaz, and González, Reyna Vergara
- Published
- 2017
24. Outcome of haematopoietic cell transplantation in children with lysosomal acid lipase deficiency: a study on behalf of the EBMT Inborn Errors Working Party
- Author
-
Su Han Lum, Milen Minkov, Simon A. Jones, Sheree Hazelaar, Tiarlan Sirait, Jane E. Potter, Polina Stepensky, Frederic Garban, Herbert Pichler, Jerry Stein, Zuhre Kaya, Ansgar Schulz, Karin Mellgren, Cristina Diaz de Heredia, Cecile Pochon, Susana Riesco, Miguel Angel Diaz, Gérard Michel, Caroline Lindemans, Bernd Gruhn, Michael H. Albert, Arjan C. Lankester, Bénédicte Neven, and Robert Wynn
- Subjects
Transplantation ,Hematology - Published
- 2023
25. Tensiones por cultura organizacional en Petróleos Mexicanos, Región Sur
- Author
-
Ballona, Arturo Cabrera and Perera, Miguel Ángel Díaz
- Published
- 2016
26. Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults
- Author
-
Metheny, Leland, Callander, Natalie S., Hall, Aric C., Zhang, Mei-Jei, Bo-Subait, Khalid, Wang, Hai-Lin, Agrawal, Vaibhav, Al-Homsi, A. Samer, Assal, Amer, Bacher, Ulrike, Beitinjaneh, Amer, Bejanyan, Nelli, Bhatt, Vijaya Raj, Bredeson, Chris, Byrne, Michael, Cairo, Mitchell, Cerny, Jan, DeFilipp, Zachariah, Perez, Miguel Angel Diaz, Freytes, César O., Ganguly, Siddhartha, Grunwald, Michael R., Hashmi, Shahrukh, Hildebrandt, Gerhard C., Inamoto, Yoshihiro, Kanakry, Christopher G., Kharfan-Dabaja, Mohamed A., Lazarus, Hillard M., Lee, Jong Wook, Nathan, Sunita, Nishihori, Taiga, Olsson, Richard F., Ringdén, Olov, Rizzieri, David, Savani, Bipin N., Savoie, Mary Lynn, Seo, Sachiko, van der Poel, Marjolein, Verdonck, Leo F., Wagner, John L., Yared, Jean A., Hourigan, Christopher S., Kebriaei, Partow, Litzow, Mark, Sandmaier, Brenda M., Saber, Wael, Weisdorf, Daniel, and de Lima, Marcos
- Published
- 2021
- Full Text
- View/download PDF
27. The Spanish Position in the Gatt Uruguay Round
- Author
-
Mier, Miguel Angel Diaz, primary
- Published
- 2019
- Full Text
- View/download PDF
28. NATwatcher: Profiling NATs in the Wild.
- Author
-
Anna Maria Mandalari, Miguel Angel Diaz Bautista, Francisco Valera, and Marcelo Bagnulo
- Published
- 2017
- Full Text
- View/download PDF
29. The Impact of Pre-Transplant Extramedullary Disease on the Outcome of Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in Children- on Behalf of PDWP/EBMT
- Author
-
Juliana Silva, Jacques-Emmanuel Galimard, Jean-Hugues Dalle, Franco Locatelli, Hawazen S. Alsaedi, Miguel Angel Diaz, Charlotte Jubert, Yves Bertrand, Giuseppina Simone, Peter Bader, Franca Fagioli, Vassiliki Kitra Roussou, Caroline Furness, Robert Wynn, Birgit Burkhardt, Alessandra Biffi, Marc Bierings, Cristina Díaz de Heredia, Arcangelo Prete, Amos Toren, Katharine Patrick, Wolfgang Holter, Arnaud Dalissier, Kanchan Rao, and Selim Corbacioglu
- Subjects
Immunology ,Cell Biology ,Hematology ,Biochemistry - Published
- 2022
30. Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis
- Author
-
Murthy, Guru Subramanian Guru, primary, Kim, Soyoung, additional, Estrada-Merly, Noel, additional, Abid, Muhammad Bilal, additional, Aljurf, Mahmoud, additional, Assal, Amer, additional, Badar, Talha, additional, Badawy, Sherif M., additional, Ballen, Karen, additional, Beitinjaneh, Amer, additional, Cerny, Jan, additional, Chhabra, Saurabh, additional, DeFilipp, Zachariah, additional, Dholaria, Bhagirathbhai, additional, Perez, Miguel Angel Diaz, additional, Farhan, Shatha, additional, Freytes, Cesar O., additional, Gale, Robert Peter, additional, Ganguly, Siddhartha, additional, Gupta, Vikas, additional, Grunwald, Michael R., additional, Hamad, Nada, additional, Hildebrandt, Gerhard C., additional, Inamoto, Yoshihiro, additional, Jain, Tania, additional, Jamy, Omer, additional, Juckett, Mark, additional, Kalaycio, Matt, additional, Krem, Maxwell M., additional, Lazarus, Hillard M, additional, Litzow, Mark, additional, Munker, Reinhold, additional, Murthy, Hemant S., additional, Nathan, Sunita, additional, Nishihori, Taiga, additional, Ortí, Guillermo, additional, Patel, Sagar S., additional, Van der Poel, Marjolein, additional, Rizzieri, David A., additional, Savani, Bipin N, additional, Seo, Sachiko, additional, Solh, Melhem, additional, Verdonck, Leo F., additional, Wirk, Baldeep, additional, Yared, Jean A., additional, Nakamura, Ryotaro, additional, Oran, Betul, additional, Scott, Bart, additional, and Saber, Wael, additional
- Published
- 2023
- Full Text
- View/download PDF
31. Insuficiencia venosa crónica
- Author
-
Aguado, Raquel Gayarre, Farrès, Nuria Piquer, Oliva, Belén Escobar, Camps, Eva María Fuentes, Pérez, Miriam Berenguer, and Herrera, Miguel Ángel Díaz
- Published
- 2016
- Full Text
- View/download PDF
32. Expanded HCT-CI Definitions Capture Comorbidity Better for Younger Patients of Allogeneic HCT for Nonmalignant Diseases
- Author
-
Broglie, Larisa, primary, Friend, Brian D., additional, Chhabra, Saurabh, additional, Logan, Brent R., additional, Bupp, Caitrin, additional, Schiller, Gary, additional, Savani, Bipin N., additional, Stadtmauer, Edward, additional, Abraham, Allistair A., additional, Aljurf, Mahmoud, additional, Badawy, Sherif M., additional, Perez, Miguel Angel Diaz, additional, Guinan, Eva C., additional, Hashem, Hasan, additional, Krem, Maxwell M., additional, Lazarus, Hillard M., additional, Rotz, Seth J., additional, Wirk, Baldeep, additional, Yared, Jean A., additional, Pasquini, Marcelo, additional, Thakar, Monica S., additional, and Sorror, Mohamed L., additional
- Published
- 2022
- Full Text
- View/download PDF
33. Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113 AML patients
- Author
-
Boyiadzis, Michael, primary, Zhang, Mei-Jie, additional, Chen, Karen, additional, Abdel-Azim, Hisham, additional, Abid, Muhammad Bilal, additional, Aljurf, Mahmoud, additional, Bacher, Ulrike, additional, Badar, Talha, additional, Badawy, Sherif M., additional, Battiwalla, Minoo, additional, Bejanyan, Nelli, additional, Bhatt, Vijaya Raj, additional, Brown, Valerie I., additional, Castillo, Paul, additional, Cerny, Jan, additional, Copelan, Edward A., additional, Craddock, Charles, additional, Dholaria, Bhagirathbhai, additional, Perez, Miguel Angel Diaz, additional, Ebens, Christen L., additional, Gale, Robert Peter, additional, Ganguly, Siddhartha, additional, Gowda, Lohith, additional, Grunwald, Michael R., additional, Hashmi, Shahrukh, additional, Hildebrandt, Gerhard C., additional, Iqbal, Madiha, additional, Jamy, Omer, additional, Kharfan-Dabaja, Mohamed A., additional, Khera, Nandita, additional, Lazarus, Hillard M., additional, Lin, Richard, additional, Modi, Dipenkumar, additional, Nathan, Sunita, additional, Nishihori, Taiga, additional, Patel, Sagar S., additional, Pawarode, Attaphol, additional, Sharma, Akshay, additional, Solh, Melhem, additional, Wagner, John L., additional, Wang, Trent, additional, Williams, Kirsten M., additional, Winestone, Lena E., additional, Wirk, Baldeep, additional, Hourigan, Christopher S., additional, Litzow, Mark, additional, Kebriaei, Partow, additional, de Lima, Marcos, additional, Page, Kristin, additional, and Weisdorf, Daniel J., additional
- Published
- 2022
- Full Text
- View/download PDF
34. Clinical Characteristics and Outcomes of COVID-19 in Pediatric and Early Adolescent and Young Adult Hematopoietic Stem Cell Transplant Recipients: A Cohort Study
- Author
-
Neel S. Bhatt, Akshay Sharma, Andrew St. Martin, Muhammad Bilal Abid, Valerie I. Brown, Miguel Angel Diaz Perez, Haydar Frangoul, Shahinaz M. Gadalla, Megan M. Herr, Maxwell M. Krem, Hillard M. Lazarus, Michael J. Martens, Parinda A. Mehta, Taiga Nishihori, Tim Prestidge, Michael A. Pulsipher, Hemalatha G. Rangarajan, Kirsten M. Williams, Lena E. Winestone, Dwight E. Yin, Marcie L. Riches, Christopher E. Dandoy, and Jeffery J. Auletta
- Subjects
Pediatric ,Transplantation ,Pediatric Research Initiative ,Adolescent ,Early adolescent and young adult ,Prevention ,Hematopoietic Stem Cell Transplantation ,COVID-19 ,Cell Biology ,Hematology ,Stem Cell Research ,Regenerative Medicine ,Hematopoietic stem cell ,Oxygen ,Cohort Studies ,Young Adult ,COVID-19 Testing ,Good Health and Well Being ,Clinical Research ,Stem Cell Research - Nonembryonic - Human ,Molecular Medicine ,Immunology and Allergy ,Humans ,Child ,Cancer - Abstract
Adult hematopoietic stem cell transplantation (HSCT) recipients are at a high risk of adverse outcomes after COVID-19. Although children have had better outcomes after COVID-19 compared to adults, data on risk factors and outcomes of COVID-19 among pediatric HSCT recipients are lacking. We describe outcomes of HSCT recipients who were ≤21 years of age at COVID-19 diagnosis and were reported to the Center for International Blood and Marrow Transplant Research between March 27, 2020, and May 7, 2021. The primary outcome was overall survival after COVID-19 diagnosis. We determined risk factors of COVID-19 as a secondary outcome in a subset of allogeneic HSCT recipients. A total of 167 pediatric HSCT recipients (135 allogeneic; 32 autologous HSCT recipients) were included. Median time from HSCT to COVID-19 was 15 months (interquartile range [IQR] 7-45) for allogeneic HSCT recipients and 16 months (IQR 6-59) for autologous HSCT recipients. Median follow-up from COVID-19 diagnosis was 53 days (range 1-270) and 37 days (1-179) for allogeneic and autologous HSCT recipients, respectively. Although COVID-19 was mild in 87% (n=146/167), 10% (n=16/167) of patients required supplemental oxygen or mechanical ventilation. The 45-day overall survival was 95% (95% confidence interval [CI], 90-99) and 90% (74-99) for allogeneic and autologous HSCT recipients, respectively. Cox regression analysis showed that patients with a hematopoietic cell transplant comorbidity index (HCT-CI) score of 1-2 were more likely to be diagnosed with COVID-19 (hazard ratio 1.95; 95% CI, 1.03-3.69, P=.042) compared to those with an HCT-CI of 0. Pediatric and early adolescent and young adult HSCT recipients with pre-HSCT comorbidities were more likely to be diagnosed with COVID-19. Overall mortality, albeit higher than the reported general population estimates, was lower when compared with previously published data focusing on adult HSCT recipients.
- Published
- 2022
35. Graft failure after 'ex-vivo' T-cell depleted haploidentical transplantation in pediatric patients with high-risk hematological malignancies. A risk factors and outcomes analysis
- Author
-
Raquel Alenda, Blanca Molina, Ivan Lopez, Alba Pereto, Miguel Ángel Moreno, Josune Zubicaray, Julián Sevilla, Marta González-Vicent, Miguel Angel Diaz, Jose L. Vicario, and Ana Castillo
- Subjects
Cancer Research ,medicine.medical_specialty ,Acute leukemia ,Graft failure ,Haploidentical transplantation ,business.industry ,T cell ,Outcome analysis ,Hematology ,Gastroenterology ,medicine.anatomical_structure ,Oncology ,Internal medicine ,medicine ,Cumulative incidence ,business ,CD8 ,Ex vivo - Abstract
Risk factors and outcomes of GF after TCD haploidentical transplantation in children with hematological malignancies were analyzed. 148 TCD transplants were included. 78 patients were diagnosed of ALL and 70 patients of AML. 22 out of 148 patients developed GF. MVA showed that patient
- Published
- 2021
36. Adapting the HCT-CI Definitions for Children, Adolescents, and Young Adults with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation
- Author
-
Brian D. Friend, Larisa Broglie, Brent R. Logan, Saurabh Chhabra, Caitrin Bupp, Gary Schiller, Amer Beitinjaneh, Miguel Angel Diaz Perez, Gregory M.T. Guilcher, Hasan Hashem, Gerhard C. Hildebrandt, Maxwell M. Krem, Hillard M. Lazarus, Taiga Nishihori, Roomi Nusrat, Seth J. Rotz, Baldeep Wirk, Matthew Wieduwilt, Marcelo Pasquini, Bipin N. Savani, Edward A. Stadtmauer, Mohamed L. Sorror, and Monica S. Thakar
- Subjects
Transplantation ,Molecular Medicine ,Immunology and Allergy ,Cell Biology ,Hematology - Abstract
Allogeneic hematopoietic cell transplantation is a curative procedure for hematologic malignancies but is associated with a significant risk of non-relapse mortality (NRM). The Hematopoietic Cell Transplantation- Comorbidity Index (HCT-CI) is a prognostic tool that discriminates this risk in all age groups. A recent survey of transplant physicians demonstrated that 79% of pediatric providers used the HCT-CI infrequently, and most reported concerns about its applicability in the younger population. We conducted a retrospective study using the Center for International Blood and Marrow Transplant Research (CIBMTR) database to examine the impact of expanded HCT-CI definitions on NRM in pediatric and young adult patients with hematologic malignancies. We included 5,790 patients40 years old receiving allogeneic transplant between 2008 and 2017 to examine broader definitions of comorbidities in the HCT-CI, including history of mechanical ventilation and fungal infection, estimated glomerular filtration rate (eGFR), and body mass index (BMI) percentiles. Multivariable Fine-Gray models were created to determine the effect of each HCT-CI defining comorbidity and its modification on NRM, and were utilized to develop two novel risk scores. We next developed the expanded HCT-CI for children and young adults (youth with malignancies; expanded ymHCT-CI), where 23% patients had an increased comorbidity score, compared to the HCT-CI. Comorbidities with hazard ratio (HR)1.2 were then removed to create the simplified HCT-CI for children and young adults (youth with malignancies; simplified ymHCT-CI), which demonstrated higher scores corresponded to a greater risk of NRM (p0.001). These novel comorbidity indices with broader definitions are more relevant to pediatric and young adult patients, and prospective studies are needed to validate these in the younger patient population. It remains to be seen if the development of these pediatric-specific and practical risk indices increases their utilization by the pediatric transplant community.
- Published
- 2022
37. Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis
- Author
-
Asad Bashey, Carolyn Mulroney, Roy F. Chemaly, Paul Castillo, Ephraim J. Fuchs, Christopher G. Kanakry, Hillard M. Lazarus, Hongtao Liu, Per Ljungman, Jeffery J. Auletta, Stefan O. Ciurea, Jennifer A. Kanakry, Miguel-Angel Perales, Muhammad Bilal Abid, Randy Taplitz, Rizwan Romee, Richard Masiarz, Soyoung Kim, Amer Beitinjaneh, Marcie L. Riches, Christopher E. Dandoy, Taiga Nishihori, Min Chen, Krishna V. Komanduri, Kristin Page, Sunita Nathan, Miguel Angel Diaz, Maxwell M. Krem, Scott R. Goldsmith, and Siddhartha Ganguly
- Subjects
Transplantation ,medicine.medical_specialty ,Cyclophosphamide ,business.industry ,Incidence (epidemiology) ,Immunology ,Congenital cytomegalovirus infection ,Cytomegalovirus ,virus diseases ,Cell Biology ,Hematology ,medicine.disease ,Biochemistry ,Gastroenterology ,Cytomegalovirus infection ,Calcineurin ,Graft-versus-host disease ,Internal medicine ,Cytomegalovirus Infections ,Humans ,Medicine ,business ,Serostatus ,medicine.drug - Abstract
Prior studies suggest increased cytomegalovirus (CMV) infection after haploidentical donor transplantation with posttransplant cyclophosphamide (HaploCy). The role of allograft source and posttransplant cyclophosphamide (PTCy) in CMV infection is unclear. We analyzed the effect of graft source and PTCy on incidence of CMV infection, and effects of serostatus and CMV infection on transplant outcomes. We examined patients reported to the Center for International Blood and Marrow Transplantation Research between 2012 and 2017 who had received HaploCy (n = 757), matched related (Sib) with PTCy (SibCy, n = 403), or Sib with calcineurin inhibitor-based prophylaxis (SibCNI, n = 1605). Cumulative incidences of CMV infection by day 180 were 42%, 37%, and 23%, respectively (P < .001). CMV disease was statistically comparable. CMV infection risk was highest for CMV-seropositive recipients (R+), but significantly higher in PTCy recipients regardless of donor (HaploCy [n = 545]: hazard ratio [HR], 50.3; SibCy [n = 279]: HR, 47.7; SibCNI [n = 1065]: HR, 24.4; P < .001). D+/R− patients also had increased risk for CMV infection. Among R+ or those developing CMV infection, HaploCy had worse overall survival and nonrelapse mortality. Relapse was unaffected by CMV infection or serostatus. PTCy was associated with lower chronic graft-versus-host disease (GVHD) overall, but CMV infection in PTCy recipients was associated with higher chronic GVHD (P = .006). PTCy, regardless of donor, is associated with higher incidence of CMV infection, augmenting the risk of seropositivity. Additionally, CMV infection may negate the chronic GVHD protection of PTCy. This study supports aggressive prevention strategies in all receiving PTCy.
- Published
- 2021
38. Neighborhood poverty and pediatric allogeneic hematopoietic cell transplantation outcomes: a CIBMTR analysis
- Author
-
C. Fred LeMaistre, Minoo Battiwalla, Amir Steinberg, Wael Saber, Biju George, Siddhartha Ganguly, Theresa Hahn, Navneet S. Majhail, Naya He, Cesar O. Freytes, Staci D. Arnold, Jennifer M. Knight, Sachiko Seo, Ruta Brazauskas, Rammurti T. Kamble, Leslie Lehmann, Richard F. Olsson, Mahmoud Aljurf, Shahrukh K. Hashmi, Miguel Angel Diaz, Alok Srivastava, Christopher E. Dandoy, Hillard M. Lazarus, Jason Law, Nandita Khera, Baldeep Wirk, Ayami Yoshimi, Haydar Frangoul, Akshay Sharma, Neel S. Bhatt, Raquel M. Schears, David Szwajcer, Jaime M. Preussler, Ibrahim Ahmed, David Gómez-Almaguer, William A. Wood, Christine Duncan, Bipin N. Savani, Sherif M. Badawy, A. Samer Al-Homsi, Kira Bona, Jignesh Dalal, Hisham Abdel-Azim, and Sara Beattie
- Subjects
Male ,Pediatrics ,medicine.medical_specialty ,Adolescent ,Databases, Factual ,Social Determinants of Health ,Immunology ,Psychological intervention ,MEDLINE ,Graft vs Host Disease ,Disease ,Infections ,Biochemistry ,Insurance Coverage ,03 medical and health sciences ,0302 clinical medicine ,Recurrence ,Cause of Death ,Neoplasms ,030225 pediatrics ,Humans ,Transplantation, Homologous ,Medicine ,Social determinants of health ,Child ,Poverty ,Hematopoietic cell ,Medicaid ,business.industry ,Hematopoietic Stem Cell Transplantation ,Infant ,Cell Biology ,Hematology ,Survival Analysis ,United States ,Transplantation ,Treatment Outcome ,surgical procedures, operative ,Child, Preschool ,030220 oncology & carcinogenesis ,Chronic Disease ,Female ,Erratum ,business ,Follow-Up Studies - Abstract
Social determinants of health, including poverty, contribute significantly to health outcomes in the United States; however, their impact on pediatric hematopoietic cell transplantation (HCT) outcomes is poorly understood. We aimed to identify the association between neighborhood poverty and HCT outcomes for pediatric allogeneic HCT recipients in the Center for International Blood and Marrow Transplant Research database. We assembled 2 pediatric cohorts undergoing first allogeneic HCT from 2006 to 2015 at age ≤18 years, including 2053 children with malignant disease and 1696 children with nonmalignant disease. Neighborhood poverty exposure was defined a priori per the US Census definition as living in a high-poverty ZIP code (≥20% of persons below 100% federal poverty level) and used as the primary predictor in all analyses. Our primary outcome was overall survival (OS), defined as the time from HCT until death resulting from any cause. Secondary outcomes included relapse and transplantation-related mortality (TRM) in malignant disease, acute and chronic graft-versus-host disease, and infection in the first 100 days post-HCT. Among children undergoing transplantation for nonmalignant disease, neighborhood poverty was not associated with any HCT outcome. Among children undergoing transplantation for malignant disease, neighborhood poverty conferred an increased risk of TRM but was not associated with inferior OS or any other transplantation outcome. Among children with malignant disease, a key secondary finding was that children with Medicaid insurance experienced inferior OS and increased TRM compared with those with private insurance. These data suggest opportunities for future investigation of the effects of household-level poverty exposure on HCT outcomes in pediatric malignant disease to inform care delivery interventions.
- Published
- 2021
39. Expanded HCT-CI Definitions Capture Comorbidity Better for Younger Patients of Allogeneic HCT for Nonmalignant Diseases
- Author
-
Larisa Broglie, Brian D. Friend, Saurabh Chhabra, Brent R. Logan, Caitrin Bupp, Gary Schiller, Bipin N. Savani, Edward Stadtmauer, Allistair A. Abraham, Mahmoud Aljurf, Sherif M. Badawy, Miguel Angel Diaz Perez, Eva C. Guinan, Hasan Hashem, Maxwell M. Krem, Hillard M. Lazarus, Seth J. Rotz, Baldeep Wirk, Jean A. Yared, Marcelo Pasquini, Monica S. Thakar, and Mohamed L. Sorror
- Subjects
Transplantation ,Molecular Medicine ,Immunology and Allergy ,Cell Biology ,Hematology - Abstract
Allogeneic hematopoietic cell transplantation (HCT) can cure many nonmalignant conditions, but concern for morbidity and mortality remains. To help physicians estimate patient-specific transplant mortality risk, the HCT comorbidity index (HCT-CI) is used. However, pediatric physicians use the HCT-CI less frequently than adult counterparts. We used the Center for International Blood and Marrow Transplant Research database to expand the HCT-CI comorbidity definitions to be more inclusive of children and adolescent and young adult (AYA) patients, adding history of mechanical ventilation, history of invasive fungal infection, assessment of chronic kidney disease (CKD) by estimated glomerular filtration rate, expanding the definition of obesity, and adding an underweight category. A total of 2815 children and AYAs (40 years old) who received first allogeneic HCT for nonmalignant diseases from 2008 to 2017 were included to create an expanded youth nonmalignant HCT-CI (expanded ynHCT-CI) and a simplified non-malignant (simplified ynHCT-CI) HCT-CI. The expanded comorbidities occurred frequently-history of mechanical ventilation (9.6%), history of invasive fungal infection (5.9%), mild CKD (12.2%), moderate/severe CKD (2.1%), obesity (10.9%), and underweight (14.5%). Thirty-nine percent of patients had an increase in their comorbidity score using the expanded ynHCT-CI, leading to a redistribution of scores: ynHCT-CI score 0 (35%), 1-2 (36.4%), and ≥3 (28.6%). Patients with an increase in their comorbidity score had an increased hazard of mortality compared to those whose score remained the same (hazard ratio = 1.41; 95% confidence interval, 1.01-1.98). Modifications to the HCT-CI can benefit children and AYA patients with nonmalignant diseases, creating a risk assessment tool that is clinically relevant and better captures comorbidity in this younger population.
- Published
- 2023
40. Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United States
- Author
-
Alois Gratwohl, Jason Law, David Szwajcer, Jean A. Yared, Bronwen E. Shaw, Ruta Brazauskas, Amer Beitinjaneh, Matthew L. Ulrickson, Hisham Abdel-Azim, Sara Beattie, Navneet S. Majhail, Shahrukh K. Hashmi, J. Douglas Rizzo, Wael Saber, Neel S. Bhatt, William A. Wood, Charles F. LeMaistre, Stephanie J. Lee, Bipin N. Savani, Sherif M. Badawy, Stefan O. Ciurea, Richard F. Olsson, David A. Rizzieri, Hasan Hashem, Sachiko Seo, Sanghee Hong, Jan Cerny, Akshay Sharma, Kyle Hebert, Hélène Schoemans, Hillard M. Lazarus, Ayami Yoshimi, Rammurti T. Kamble, Siddhartha Ganguly, Nosha Farhadfar, Theresa Hahn, Miguel Angel Diaz, Nandita Khera, Mahmoud Aljurf, and Usama Gergis
- Subjects
Male ,Cancer Research ,0302 clinical medicine ,Risk Factors ,80 and over ,Medicine ,030212 general & internal medicine ,Cancer ,Aged, 80 and over ,community health ,Framingham Risk Score ,Hazard ratio ,Hematopoietic Stem Cell Transplantation ,Hematology ,Middle Aged ,allogeneic transplant ,Treatment Outcome ,Local ,Oncology ,Hematologic Neoplasms ,030220 oncology & carcinogenesis ,Community health ,Public Health and Health Services ,Female ,Public Health ,Homologous ,Adult ,medicine.medical_specialty ,Adolescent ,Oncology and Carcinogenesis ,survival ,Community Health Planning ,Article ,Young Adult ,03 medical and health sciences ,Clinical Research ,Internal medicine ,Transplantation, Homologous ,Humans ,Nonrelapse mortality ,hematopoietic cell transplantation ,Oncology & Carcinogenesis ,Aged ,Transplantation ,Hematopoietic cell ,business.industry ,Prevention ,United States ,Neoplasm Recurrence ,Good Health and Well Being ,Increased risk ,Bone transplantation ,Neoplasm Recurrence, Local ,business - Abstract
Background The association of community factors and outcomes after hematopoietic cell transplantation (HCT) has not been comprehensively described. Using the County Health Rankings and Roadmaps (CHRR) and the Center for International Blood and Marrow Transplant Research (CIBMTR), this study evaluated the impact of community health status on allogeneic HCT outcomes. Methods This study included 18,544 adult allogeneic HCT recipients reported to the CIBMTR by 170 US centers in 2014-2016. Sociodemographic, environmental, and community indicators were derived from the CHRR, an aggregate community risk score was created, and scores were assigned to each patient (patient community risk score [PCS]) and transplant center (center community risk score [CCS]). Higher scores indicated less healthy communities. The impact of PCS and CCS on patient outcomes after allogeneic HCT was studied. Results The median age was 55 years (range, 18-83 years). The median PCS was -0.21 (range, -1.37 to 2.10; standard deviation [SD], 0.42), and the median CCS was -0.13 (range, -1.04 to 0.96; SD, 0.40). In multivariable analyses, a higher PCS was associated with inferior survival (hazard ratio [HR] per 1 SD increase, 1.04; 99% CI, 1.00-1.08; P = .0089). Among hematologic malignancies, a tendency toward inferior survival was observed with a higher PCS (HR, 1.04; 99% CI, 1.00-1.08; P = .0102); a higher PCS was associated with higher nonrelapse mortality (NRM; HR, 1.08; 99% CI, 1.02-1.15; P = .0004). CCS was not significantly associated with survival, relapse, or NRM. Conclusions Patients residing in counties with a worse community health status have inferior survival as a result of an increased risk of NRM after allogeneic HCT. There was no association between the community health status of the transplant center location and allogeneic HCT outcomes.
- Published
- 2020
41. Plerixafor‐based mobilization in pediatric healthy donors with unfavorable donor/recipient body weight ratio resulted in a better <scp>CD34</scp> + collection yield: A retrospective analysis
- Author
-
Manuel Ramírez, Marta González-Vicent, Josune Zubicaray, Elena Sebastián, Blanca Molina, Ana Castillo, Miguel Angel Diaz, Luis Madero, Eva M. Galvez, and Julián Sevilla
- Subjects
medicine.medical_specialty ,Mobilization ,business.industry ,Plerixafor ,CD34 ,Urology ,Hematology ,General Medicine ,030204 cardiovascular system & hematology ,Body weight ,Transplantation ,03 medical and health sciences ,0302 clinical medicine ,Apheresis ,Cell dose ,medicine ,Retrospective analysis ,business ,030215 immunology ,medicine.drug - Abstract
INTRODUCTION In order to propose risk-adapted mobilization algorithms, several authors have tried to look for predictive factors of the CD34+ yield in healthy pediatric donors. Donor recipient body weight ratio (D/R ratio) was identified as one of the main variables related with the success to achieve the target cell dose for transplantation. According to this variable we modified the mobilization schedule. MATERIAL AND METHODS We report the results of 46 mobilizations and apheresis procedures performed in our center with unfavorable D/R ratio. Mobilization was attempted by the standard regime of G-CSF (10 mcg/kg/24 hours) in 28 cases (60.9%), with high dose G-CSF (10 mcg/kg/12 hours) in 9 cases (19.6%), and with plerixafor and G-CSF single dose regime in 9 cases (19.6%). RESULTS CD34+ cell quantification before apheresis is closely related to CD34+ yield, being the only factor related to collected CD34+ cells (beta .71; P
- Published
- 2020
42. Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors
- Author
-
Guru Subramanian Guru Murthy, Soyoung Kim, Zhen-Huan Hu, Noel Estrada-Merly, Muhammad Bilal Abid, Mahmoud Aljurf, Ulrike Bacher, Sherif M. Badawy, Amer Beitinjaneh, Chris Bredeson, Jean-Yves Cahn, Jan Cerny, Miguel Angel Diaz Perez, Nosha Farhadfar, Robert Peter Gale, Siddhartha Ganguly, Usama Gergis, Gerhard C. Hildebrandt, Michael R. Grunwald, Shahrukh Hashmi, Nasheed M. Hossain, Matt Kalaycio, Rammurti T. Kamble, Mohamed A. Kharfan-Dabaja, Betty Ky Hamilton, Hillard M. Lazarus, Jane Liesveld, Mark Litzow, David I. Marks, Hemant S. Murthy, Sunita Nathan, Aziz Nazha, Taiga Nishihori, Sagar S. Patel, Attaphol Pawarode, David Rizzieri, Bipin Savani, Sachiko Seo, Melhem Solh, Celalettin Ustun, Marjolein van der Poel, Leo F. Verdonck, Ravi Vij, Baldeep Wirk, Betul Oran, Ryotaro Nakamura, Bart Scott, Wael Saber, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, and MUMC+: MA Hematologie (9)
- Subjects
Adult ,Male ,Cancer Research ,Transplantation Conditioning ,BLOOD ,IMPACT ,BONE-MARROW ,Graft vs Host Disease ,ACUTE MYELOID-LEUKEMIA ,Disease-Free Survival ,Cohort Studies ,AGE ,Humans ,610 Medicine & health ,Aged ,Retrospective Studies ,Original Investigation ,Siblings ,Hematopoietic Stem Cell Transplantation ,Middle Aged ,STEM ,RECIPIENTS ,Oncology ,Myelodysplastic Syndromes ,Neoplasm Recurrence, Local ,Unrelated Donors ,SYSTEM - Abstract
Importance Matched sibling donors (MSDs) are preferred for allogeneic hematopoietic cell transplantation (allo-HCT) in myelodysplastic syndrome even if they are older. However, whether older MSDs or younger human leukocyte antigen-matched unrelated donors (MUDs) are associated with better outcomes remains unclear. Objective To investigate whether allo-HCT for myelodysplastic syndrome using younger MUDs would be associated with improved disease-free survival and less relapse compared with older MSDs. Design, Setting, and Participants This retrospective cohort study assessed data reported to the Center for International Blood and Marrow Transplant Research database from 1761 adults 50 years or older with myelodysplastic syndrome who underwent allo-HCT using an older MSD or younger MUD between January 1, 2011, and December 31, 2017, with a median follow-up of 48 months. Data analysis was performed from January 8, 2019, to December 30, 2020. Interventions/Exposures Allo-HCT from an older MSD (donor age ���50 years) or a younger MUD (donor age ���35 years). Main Outcomes and Measures The primary outcome was disease-free survival. Secondary outcomes were overall survival, relapse, nonrelapse mortality, acute graft-vs-host disease (GVHD), chronic GVHD, and GVHD-free relapse-free survival. Results Of 1761 patients (1162 [66%] male; median [range] age, 64.9 [50.2-77.6] years in the MSD cohort and 66.5 [50.4-80.9] years in MUD cohort), 646 underwent allo-HCT with an older MSD and 1115 with a younger MUD. In multivariable analysis, the rate of disease-free survival was significantly lower in allo-HCTs with older MSDs compared with younger MUDs (hazard ratio [HR], 1.17; 95% CI, 1.02-1.34; P���=���.02), whereas the difference in overall survival rate of allo-HCT with younger MUDs vs older MSDs was not statistically significant (HR, 1.13; 95% CI, 0.98-1.29; P���=���.07). Allo-HCT with older MSDs was associated with significantly higher relapse (HR, 1.62; 95% CI, 1.32-1.97; P���
- Published
- 2022
43. Corrosion risk assessment methodology by desalinated water supply in drinking water networks
- Author
-
Miguel Angel Diaz Hurtado, Sara Espinosa, David Aguilera, Susana González, Manuel Argamasilla, and Alicia Piñero
- Published
- 2022
44. Correction to: An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis
- Author
-
Antonio M. Jimenez Jimenez, Marcos De Lima, Krishna V. Komanduri, Trent P. Wang, Mei-Jie Zhang, Karen Chen, Hisham Abdel-Azim, Muhammad Bilal Abid, Mahmoud Aljurf, Hassan Alkhateeb, Amer Assal, Ulrike Bacher, Frédéric Baron, Minoo Battiwalla, Amer Beitinjaneh, Nelli Bejanyan, Vijaya Raj Bhatt, Michael Byrne, Jean-Yves Cahn, Mitchell Cairo, Paul Castillo, Edward Copelan, Zachariah DeFilipp, Miguel Angel Diaz Perez, Mahmoud Elsawy, Robert Peter Gale, Biju George, Michael R. Grunwald, Gerhard C. Hildebrandt, William J. Hogan, Christopher G. Kanakry, Ankit Kansagra, Mohamed A. Kharfan-Dabaja, Nandita Khera, Maxwell M. Krem, Aleksandr Lazaryan, Joseph Maakaron, Rodrigo Martino, Joseph McGuirk, Fotios V. Michelis, Giuseppe Milone, Asmita Mishra, Hemant S. Murthy, Alberto Mussetti, Sunita Nathan, Taiga Nishihori, Richard F. Olsson, Neil Palmisiano, Sagar Patel, Ayman Saad, Sachiko Seo, Akshay Sharma, Melhem Solh, Leo F. Verdonck, Baldeep Wirk, Jean A. Yared, Mark Litzow, Partow Kebriaei, Christopher S. Hourigan, Wael Saber, and Daniel Weisdorf
- Subjects
Transplantation ,Hematology ,610 Medicine & health - Published
- 2022
- Full Text
- View/download PDF
45. HEV infection in stem cell transplant recipients-retrospective study of EBMT Infectious Diseases Working Party
- Author
-
Nicole M. A. Blijlevens, Diana Averbuch, Hervé Ghesquières, Christian Koenecke, Rafael de la Cámara, Marc Bierings, José Luis Piñana, Miguel Angel Diaz, Nicolaus Kröger, Malgorzata Mikulska, Jakob Passweg, Nina Knelange, Hélène Labussière-Wallet, Olaf Penack, Lotus Wendel, Jan Styczyński, Anke H W Bruns, Antonia Sampol, Jan J. Cornelissen, and Hematology
- Subjects
medicine.medical_specialty ,medicine.medical_treatment ,viruses ,Communicable Diseases ,chemistry.chemical_compound ,Immunocompromised Host ,SDG 3 - Good Health and Well-being ,Internal medicine ,Ribavirin ,Hepatitis E virus ,Medicine ,Humans ,Cause of death ,Retrospective Studies ,Hepatitis ,Transplantation ,business.industry ,virus diseases ,Retrospective cohort study ,Immunosuppression ,Hematology ,medicine.disease ,Transplant Recipients ,digestive system diseases ,Chronic infection ,Late diagnosis ,chemistry ,RNA ,Stem cell ,business ,Stem Cell Transplantation ,Rare cancers Radboud Institute for Health Sciences [Radboudumc 9] - Abstract
Item does not contain fulltext HEV infection is an emerging cause of acute and chronic hepatitis in stem cell transplant (SCT) recipients. We performed a retrospective observational study among EBMT centers with the aim of describing characteristics, management and outcome of HEV after SCT. There were 34 cases of HEV infection from 12 centers in 6 countries, diagnosed in median 4.5 months after SCT; 20 of acute and 14 of chronic infection. Non-hepatic findings possibly associated with HEV infection were present in 9 (26%). Patients with chronic infection had more characteristics associated with severely immunocompromised status. Ribavirin was provided to 16 patients (47%; 40% with acute and 57% with chronic infection), in median for 75 days. Three (19%) patients discontinued it due to side effects. HEV-RNA clearance occurred in 29 patients (85%; 85% in acute and 86% in chronic infection). HEV was considered a cause of death in 3 (9%), with 2 cases with late diagnosis. Reduction of immunosuppression in those receiving it, and ribavirin treatment in those with chronic infection were associated with shorter time to HEV-RNA clearance. Policy on HEV testing varied between the centers. In conclusion, acute and chronic HEV hepatitis should be promptly diagnosed and managed in SCT recipients.
- Published
- 2022
46. Clinical Features and Outcomes Associated with Bronchial Asthma Among COVID-19 Hospitalized Patients
- Author
-
Miguel Angel Diaz, Nelly Catalan-Caceres, Thais C Beauperthuy, Carlos Domingo, Ethel Ibañez, Carmen Morata, and Alfredo De Diego
- Subjects
Pulmonary and Respiratory Medicine ,Journal of Asthma and Allergy ,Immunology and Allergy - Abstract
Miguel Angel Diaz,1 Nelly Catalan-Caceres,1 Thais C Beauperthuy,2 Carlos Domingo,1 Ethel Ibañez,1 Carmen Morata,3 Alfredo De Diego2 1Allergy Department, Hospital Universitari I Politècnic La Fe, Valencia, Spain; 2Respiratory Department, Hospital Universitari I Politècnic La Fe, Valencia, Spain; 3Internal Medicine Department, Hospital Universitari I Politècnic La Fe, Valencia, SpainCorrespondence: Miguel Angel Diaz, Allergy Department, Hospital Universitari I Politècnic La Fe, Avinguda de Fernando Abril Martorell, 106, Valencia, 46026, Spain, Tel +34 961244084, Email diaz_mig@gva.esBackground: The impact of diagnosis treatment and bronchial asthma on coronavirus disease 2019 (COVID-19) associated outcomes remains unclear.Objective: To identify the prevalence and outcomes associated with asthma among hospitalized patients with COVID-19.Methods: Electronic health records of 130 patients with asthma among hospitalized patients with COVID-19 were reviewed. Two subgroups of asthmatic patients were compared according to clinical outcomes during hospitalization. Patients with death results, intubation, and/or need of intensive care unit (ICU) stay were grouped as asthmatic patients with severe COVID-19 outcomes, and the rest were grouped as asthmatic patients with non-severe COVID-19 outcomes. Multivariable analyses were conducted with logistic regression to identify independent risk factors for severe outcomes.Results: The prevalence of asthma in COVID-19 hospitalized patients was 5%. The mean age was 59.4 years and 54% were women. 17% received treatment in GINA step 4â 5 asthma at the time of admission. An allergic asthma phenotype was determined in 38%. There was no significant difference in hospital length of stay or need for intubation between asthmatic patients and global COVID-19 admitted patients. 17% of asthmatic patients developed a severe outcome, and 5% had a death result. Elevated Lactate Dehydrogenase (LDH) level, low transcutaneous pulse oximetry (SpO2), the coexistence of atrial fibrillation (AF), and need for moderate or high ICS at admission were independent risk factors for a worse outcome in asthmatics COVID-19 hospitalized patients.Conclusion: The prevalence of asthma in COVID-19 hospitalized patients was 5%, consistent with the asthma prevalence in the general population. The asthmatic patients with the previous prescription of moderate or high doses of ICS and/or coexistence of atrial fibrillation at admission had a higher risk of the severe outcome.Keywords: bronchial asthma, COVID-19, risk factors, outcomes
- Published
- 2022
47. 18 - Emergencias extrahospitalarias específicas: sistemática de actuación
- Author
-
Barranquero, Francisca Gema Cazorla, Muñoz, Fidel Alberto Hijano, Quintero, Juan Pablo Valencia, Fernández-Castanys, Esteban Feriche, Guadarrama, Luis Roberto Jiménez, Castellanos, Miguel Ángel Díaz, and Torrús, Andrés Estivill
- Published
- 2022
- Full Text
- View/download PDF
48. 17 - Asistencia extrahospitalaria urgente: generalidades
- Author
-
Quintero, Juan Pablo Valencia, Bailón, Ana Pérez, Barranquero, Francisca Gema Cazorla, Castellanos, Miguel Ángel Díaz, Fernández-Castanys, Esteban Feriche, and López, Javier Ignacio Martín
- Published
- 2022
- Full Text
- View/download PDF
49. Role of the mesenchymal stromal cells in bone marrow failure of Fanconi Anemia patients
- Author
-
Josune Zubicaray, Maria Ivanova, June Iriondo, Jorge García Martínez, Rafael Muñoz-Viana, Lorea Abad, Lorena García-García, Jesús González de Pablo, Eva Gálvez, Elena Sebastián, Manuel Ramírez, Luis Madero, Miguel Ángel Díaz, África González-Murillo, and Julián Sevilla
- Subjects
mesenchymal stromal cells ,bone marrow microenvironment ,bone marrow failure ,gene therapy ,Fanconi anemia ,Biology (General) ,QH301-705.5 - Abstract
IntroductionFanconi anemia (FA) is an inherited disorder characterized by bone marrow failure, congenital malformations, and predisposition to malignancies. Alterations in hematopoietic stem cells (HSC) have been reported, but little is known regarding the bone marrow (BM) stroma. Thus, the characterization of Mesenchymal Stromal Cells (MSC) would help to elucidate their involvement in the BM failure.MethodsWe characterized MSCs of 28 FA patients (FA-MSC) before and after treatment (hematopoietic stem cell transplantation, HSCT; or gene therapy, GT). Phenotypic and functional properties were analyzed and compared with MSCs expanded from 26 healthy donors (HD-MSCs). FA-MSCs were genetically characterized through, mitomycin C-test and chimerism analysis. Furthermore, RNA-seq profiling was used to identify dysregulated metabolic pathways.ResultsOverall, FA-MSC had the same phenotypic and functional characteristics as HD-MSC. Of note, MSC-GT had a lower clonogenic efficiency. These findings were not confirmed in the whole FA patients’ cohort. Transcriptomic profiling identified dysregulation in HSC self-maintenance pathways in FA-MSC (HOX), and was confirmed by real-time quantitative polymerase chain reaction (RT-qPCR).DiscussionOur study provides a comprehensive characterization of FA-MSCs, including for the first time MSC-GT and constitutes the largest series published to date. Interestingly, transcript profiling revealed dysregulation of metabolic pathways related to HSC self-maintenance. Taken together, our results or findings provide new insights into the pathophysiology of the disease, although whether these niche defects are involved in the hematopoietic defects seen of FA deserves further investigation.
- Published
- 2024
- Full Text
- View/download PDF
50. Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report
- Author
-
Michael Byrne, Jane L. Liesveld, Richard F. Olsson, Sagar S. Patel, Hongtao Liu, Eric Wong, Brenda M. Sandmaier, Bipin N. Savani, Hannah Choe, Partow Kebriaei, Gulrayz Ahmed, Tania Jain, Moussab Damlaj, Rebecca L. Olin, Mehdi Hamadani, Uday R. Popat, Neil Palmisiano, Rajneesh Nath, Mei-Jie Zhang, Mark R. Litzow, Attaphol Pawarode, Mark P. Hertzberg, Taiga Nishihori, Arnon Nagler, Jean A. Yared, Mitchell S. Cairo, Ioannis Politikos, Michael R. Grunwald, Hisham Abdel-Azim, Usama Gergis, David A. Rizzieri, Baldeep Wirk, Ashish Bajel, Rammurti T. Kamble, Hemant S. Murthy, Jean-Yves Cahn, Corey Cutler, Mahmoud Aljurf, A. Samer Al-Homsi, Geoffrey L. Uy, Miguel-Angel Perales, Muhammad Waqas Khan, Miguel Angel Diaz, Minocher Battiwalla, Mohamed A. Kharfan-Dabaja, Nosha Farhadfar, Natasha Kekre, Vaibhav Agrawal, Hillard M. Lazarus, Jan Cerny, Rodrigo Martino, Nandita Khera, Youjin Wang, Asmita Mishra, Nasheed Hossain, Luis Isola, Leo F. Verdonck, Nirav N. Shah, Vijaya Raj Bhatt, Zachariah DeFilipp, Daniel J. Weisdorf, Vikram Mathews, Edward A. Copelan, Aaron T. Gerds, C. Esar O. Freytes, David Valc A. Arcel, Shahrukh K. Hashmi, Mrinal M. Patnaik, Sunita Nathan, Sachiko Seo, Marcos de Lima, Qaiser Bashir, David I. Marks, Zheng Zhou, Yoshihiro Inamoto, Ryotaro Nakamura, Hai-Lin Wang, Edmund K. Waller, James M. Foran, Gerhard C. Hildebrandt, Amer Assal, Zartash Gul, Hassan B. Alkhateeb, Ulrike Bacher, and Wael Saber
- Subjects
Adult ,Melphalan ,medicine.medical_specialty ,Transplantation Conditioning ,medicine.medical_treatment ,Hematopoietic stem cell transplantation ,Gastroenterology ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Humans ,610 Medicine & health ,Busulfan ,business.industry ,Hematopoietic Stem Cell Transplantation ,Hematology ,Total body irradiation ,medicine.disease ,Fludarabine ,Transplantation ,Leukemia, Myeloid, Acute ,Leukemia ,Alemtuzumab ,Erratum ,business ,medicine.drug - Abstract
There is a lack of large comparative study on the outcomes of reduced intensity conditioning (RIC) in acute myeloid leukemia (AML) transplantation using fludarabine/busulfan (FB) and fludarabine/melphalan (FM) regimens. Adult AML patients from Center for International Blood and Marrow Transplant Research who received first RIC allo-transplant between 2001 and 2015 were studied. Patients were excluded if they received cord blood or identical twin transplant, total body irradiation in conditioning, or graft-versus-host disease (GVHD) prophylaxis with in vitro T-cell depletion. Primary outcome was overall survival (OS), secondary end points were leukemia-free survival (LFS), nonrelapse mortality (NRM), relapse, and GVHD. Multivariate survival model was used with adjustment for patient, leukemia, and transplant-related factors. A total of 622 patients received FM and 791 received FB RIC. Compared with FB, the FM group had fewer transplant in complete remission (CR), fewer matched sibling donors, and less usage of anti-thymocyte globulin or alemtuzumab. More patients in the FM group received marrow grafts and had transplantation before 2005. OS was significantly lower within the first 3 months posttransplant in the FM group (hazard ratio [HR] = 1.82, P < .001), but was marginally superior beyond 3 months (HR = 0.87, P = .05). LFS was better with FM compared with FB (HR = 0.89, P = .05). NRM was significantly increased in the FM group during the first 3 months of posttransplant (HR = 3.85, P < .001). Long-term relapse was lower with FM (HR = 0.65, P < .001). Analysis restricted to patients with CR showed comparable results. In conclusion, compared with FB, the FM RIC showed a marginally superior long-term OS and LFS and a lower relapse rate. A lower OS early posttransplant within 3 months was largely the result of a higher early NRM.
- Published
- 2020
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.